@article{AMJ3833,
author = {Bin Yu and Xinwei Wang and Zhiqiang Qin and Jianxin Xue and Hongzhou Cai and Chuanjie Zhang and Weizhang Xu and Jingyuan Wang and Xiao Li and Zicheng Xu and Ting Xu and Qing Zou},
title = {The association between let-7 microRNA-binding site polymorphism rs712 and cancer risk: a meta-analysis and trial sequential analysis},
journal = {AME Medical Journal},
volume = {2},
number = {5},
year = {2017},
keywords = {},
abstract = {Background: Previous studies have investigated the relationship between let-7 microRNA-binding site polymorphism rs712 and cancer susceptibility. However, the available conclusions remained inconsistent. The present meta-analysis was thus performed to clarify such associations.
Methods: A meta-analysis including 11 studies was performed with 3,572 cases and 4,749 controls. Relevant studies were searched in the databases EMBASE, PubMed and Web of Science, covering relevant papers published until September 1st, 2016. We pooled data with odds ratios (ORs) and 95% confidence intervals (CIs) to assess the strength of the associations. Besides, Begg’s funnel plots and Egger’s regression test were utilized to evaluate publication bias. Furthermore, we took advantage of trial sequential analysis to evaluate whether the evidence of the results was sufficient.
Results: Overall, the results showed that significant cancer risk was associated with rs712 for heterozygote model OR =1.10 (95% CI: 1.002–1.22), homozygote model OR =1.71 (95% CI: 1.18–2.49), dominant model OR =1.19 (95% CI: 1.04–1.35), recessive model OR=1.64 (95% CI: 1.17–2.31) and allele model OR =1.21 (95% CI: 1.06–1.39). Moreover, trial sequential analyses for the first time were performed to confirm such associations, demonstrating that the results of our study were based on sufficient evidence.
Conclusions: This results of the meta-analysis suggested that rs712 polymorphism was associated with cancer susceptibility, which might act as a potential biomarker for evaluating cancer risk.},
issn = {2520-0518}, url = {https://amj.amegroups.org/article/view/3833}
}